Brixmor Property Group Inc (BRX) Stock News

Brixmor Property (BRX), a New York-based shopping center owner and operator, offers an attractive dividend yield of 4.2% with a current annualized dividend of $1.23, up 7% year-over-year. The company has increased its dividend 5 times over the last 5 years with an average annual increase of 7.56%. With a solid payout ratio of 53% and expected earnings growth of 4.89% for 2026, BRX presents a compelling opportunity for income investors, though it carries a Zacks Rank of #3 (Hold).

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether insiders are receiving substantial benefits unavailable to ordinary shareholders and whether transaction terms limit competing offers. The investigations cover Forte Biosciences' sale to argenx, Luxfer Holdings' sale to Wynnchurch Capital affiliates, Sanara MedTech's sale to MiMedx Group, and MarketAxess Holdings' sale to Intercontinental Exchange.

Halper Sadeh LLC, an investor rights law firm, is investigating Forte Biosciences' $77.00 per share sale to argenx and Safety Insurance Group's $105.00 per share sale to a Mapfre affiliate for potential securities law violations and breaches of fiduciary duties. The firm is seeking increased consideration, additional disclosures, and other relief on behalf of shareholders.

Pomerantz Law Firm has filed class action lawsuits against ImmunityBio, Inc., New Era Energy & Digital, Inc., and Vital Farms, Inc. for alleged securities fraud and unlawful business practices. The primary case involves ImmunityBio, which faced an FDA warning letter on March 24, 2026, for continuing to promote its bladder-cancer drug Anktiva in a misleading manner despite previous warnings. The disclosure triggered a 21.12% stock price decline. Investors have until May 26, 2026, to request Lead Plaintiff status.

Rosen Law Firm reminds ImmunityBio investors of the May 26, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements about Anktiva's capabilities and ImmunityBio's business operations. Investors who purchased securities between January 19, 2026 and March 24, 2026 may be entitled to compensation.

The Schall Law Firm is seeking investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its Anktiva drug capabilities, causing investor losses when the truth was revealed.

Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.

ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter regarding misleading efficacy claims made by executive chairman Dr. Patrick Soon-Shiong about the company's drug Anktiva. The FDA determined that promotional materials falsely suggested Anktiva could treat all cancers, when it is only approved for non-muscle invasive bladder cancer. The announcement caused IBRX shares to plunge over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization. Hagens Berman is investigating claims that ImmunityBio intentionally misled investors.

The Gross Law Firm has issued a shareholder alert for ImmunityBio, Inc. (NASDAQ: IBRX) regarding a securities class action lawsuit. The complaint alleges that defendants issued materially false and misleading statements about Anktiva's capabilities during the class period of January 19, 2026 to March 24, 2026. Shareholders who purchased shares during this period are encouraged to register by the May 26, 2026 deadline.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Atara Biotherapeutics (ATRA), Coty Inc. (COTY), Super Micro Computer (SMCI), and ImmunityBio (IBRX). The lawsuits allege that defendants made false or misleading statements regarding their business operations and prospects. Lead plaintiff deadlines range from May 22-26, 2026.

A securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) for investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges material misstatements regarding the company's lead product Anktiva, including false claims that it is a cancer vaccine and can cure all cancers. The FDA issued a Warning Letter on March 24, 2026, citing inaccurate claims made by the company's Executive Chairman. Following this disclosure, IBRX stock fell 21.12% to $7.42 per share. The deadline to seek lead plaintiff status is May 26, 2026.

Rosen Law Firm is reminding investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 of the May 26, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements about Anktiva's capabilities and ImmunityBio's business operations and prospects.

Rosen Law Firm is urging ImmunityBio, Inc. investors who purchased securities between January 19, 2026 and March 24, 2026 and suffered losses exceeding $100,000 to secure legal counsel before the May 26, 2026 deadline. The firm has filed a securities class action lawsuit alleging that defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false and misleading stat